VIVUS — Investor Presentation (April 2014)
27 slides from VIVUS's investor presentation, Apr 8, 2014
Slide 1: Innovative Therapies Novel Products
INNOVATIVE THERAPIES NOVEL PRODUCTS April 2014 ©2014 VIVUS Inc. All rights reserved | www.vivus.com
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation contains "forward-looking" statements that involve risks and uncertainties. These statements typically may be identified by the use of forward-looking words or phrases such as "may," "believe," "expect," "forecast," "intend," "anticipate," "predict," "shou
Slide 3: VIVUS Priorities - 2014
VIVUS PRIORITIES - 2014 Drive Qsymia Demand Increase Third Party Coverage for Qsymia Enhance Direct-to-Patient Programs Establish a Qsymia Commercial Alliance Maintain Positive Momentum for STENDRA/SPEDRA Alliances ©2014 VIVUS Inc. All rights reserved | www.vivus.com 2
Slide 4: Obesity Market & Qsymia
Obesity Market & Qsymia 3 ©2014 VIVUS Inc. All rights reserved | www.vivus.com
Slide 5: U.S. Obese and Overweight with a Co-morbidity Population
U.S. Obese and Overweight w/ a co-morbidity population1 Over 110 million US adults are obese or overweight with a weight-related comorbidity Approximately 40% are currently on drug therapy for at least one co-morbidity3, while only ~2% are on drug therapy for obesity SOURCE: NHANES (2010); VIVUS, In
Slide 6: Qsymia Prescribing Information
QSYMIA PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 5 About Qsymia Qsymia is indicated as an adjunct to a reducedcalorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) o
Slide 7: Qsymia Magnitude of Effect: Pivotal 1-Year Studies
QSYMIA MAGNITUDE OF EFFECT PIVOTAL 1-YEAR STUDIES: WEIGHT LOSS OVER TIME (OBSERVED/ITT DATA) ©2013 VIVUS Inc. All rights reserved | www.vivus.com 6 Study 1 (EQUIP1) Study 2 (CONQUER2) Time (Week) Time (Week) 56 ITT-LOCF 56 ITT-LOCF All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or
Slide 8: Qsymia Consistency of Effect
QSYMIA CONSISTENCY OF EFFECT ©2013 VIVUS Inc. All rights reserved | www.vivus.com 7 *Dvorak, R., Peterson, C., Day, W. Application of Proposed Treatment Algorithm (PTA) Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release Topiramate (PHEN/TPM ER) Presented at The Obesity Society 30
Slide 9: Beneficial Effects of Weight Loss with Qsymia
BENEFICIAL EFFECTS OF WEIGHT LOSS WITH QSYMIA ©2013 VIVUS Inc. All rights reserved | www.vivus.com 8 Diastolic BP Systolic BP Fibrinogen Triglycerides TChol:HDL IWQOL total Fasting glucose HOMA-IR Fasting insulin HbA1c hs-CRP ALT Apnea Hypopnea Index Placebo subtracted effect size Placebo subtracted
Slide 10: Recent Publications Support the Benefit-Risk Profile of Qsymia
RECENT PUBLICATIONS SUPPORT THE BENEFIT-RISK PROFILE OF QSYMIA “Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended-Release” W. Timothy Garvey, MD, et al. Diabetes Care1 Patients on Recommended (7.5/46) and Top (15/92) do
Slide 11: Obesity Treatment Evolution
Obesity Treatment Evolution 10 ©2014 VIVUS Inc. All rights reserved | www.vivus.com
Slide 12: AACE Treatment Algorithm: Medical Therapy Is Recommended
AACE TREATMENT ALGORITHM: MEDICAL THERAPY IS RECOMMENDED 11 Obesity management and FDA-approved anti-obesity medications now recommended for: Prediabetes Diabetes Dyslipidemia Hypertension 1st ever inclusion of drug therapy in treatment algorithm Primary Care Physicians refer to AACE algorithm ©2014
Slide 13: Greater Recognition of Obesity as a Disease, Pharmacotherapy as a Treatment Option
GREATER RECOGNITION OF OBESITY AS A DISEASE, PHARMACOTHERAPY AS A TREATMENT OPTION Obesity is now recognized as a disease by the leading medical association in the U.S. AMA recognition is important support for policy makers, healthcare providers and payors Additional recent publications support long
Slide 14: Qsymia Commercialization
Qsymia Commercialization 13 ©2014 VIVUS Inc. All rights reserved | www.vivus.com
Slide 15: Healthcare Provider Targeting
HEALTHCARE PROVIDER TARGETING Re-prioritized targets based on prescribing behavior and other factors Analyzed and redefined territories Reconfigured and redeployed sales resources against highest value targets ©2013 VIVUS Inc. All rights reserved | www.vivus.com 14
Slide 16: Healthcare Provider Engagement
HEALTHCARE PROVIDER ENGAGEMENT Ongoing education process (guidelines; clinical data) Focus for new starts on high-need patient (BMI>35) Provides an avenue for Qsymia trial and adoption Maintain Free Trial Offer (14 days of Starting Dose) Works as a two-week sample; lowers out-of-pocket $ for patient
Slide 17: Qsymia Reimbursement Continues to Improve
QSYMIA REIMBURSEMENT CONTINUES TO IMPROVE Qsymia Coverage: YE2014 Goal = 50% As of Feb-2014, 29% of Qsymia TRxs were covered by insurance 2014 Focus: Pull-through & Improved access ©2014 VIVUS Inc. All rights reserved | www.vivus.com 16
Slide 18: OPM Issues New Directive to Carriers
U.S. OFFICE OF PERSONNEL MANAGEMENT (OPM) ISSUES NEW DIRECTIVE TO CARRIERS 20-Mar-2014 - OPM Letter to all Federal Employees Health Benefits (FEHB) Carriers: “Diet and exercise are the preferred methods for losing weight.” “Additionally, drug therapy can assist obese adults who do not achieve weight
Slide 19: Shari Belafonte, Obesity Spokesperson
SHARI BELAFONTE, OBESITY SPOKESPERSON Inspired to Lose starring Shari Belafonte VIVUS sponsored program to encourage patient-physician dialog about weight Satellite Media Tour 38.8 million impressions* to date *aired/published and pending stories 200+ TV broadcasts www.inspiredlosing.com ©2013 VIVUS
Slide 20: Qsiva | CVOT | Qsymia IP
Qsiva | CVOT | Qsymia IP 19 ©2014 VIVUS Inc. All rights reserved | www.vivus.com
Slide 21: Qsymia European Strategy
QSYMIA EUROPEAN STRATEGY Goal Satisfy FDA post-approval requirements with a single CVOT (AQCLAIM/OB-401) that may also support EU registration Strategy Create interim analysis CVOT so that ~two years of data may be used to support an application while trial continues Tactics Dialog with Scientific A
Slide 22: AQCLAIM Study (CVOT)
AQCLAIM STUDY (CVOT) A Qsymia® CardiovascuLAr morbIdity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease Primary Efficacy Endpoint: Time to 1st occurrence of nonfatal MI, nonfatal stroke or CV death Number of Subjects: ~11,000 - 16,000 Number of Sites: ~450 (North Ame
Slide 23: New Patents Extend Qsymia Coverage to Mid-2029
NEW PATENTS EXTEND QSYMIA COVERAGE TO MID-2029 USPTO has issued two new VIVUS patents with claims covering QSYMIA, extending coverage by nine years U.S. Patent No. 8,580,298 26 claims directed to unit dosage forms or packaged pharmaceutical preparations U.S. Patent No. 8,580,299 Nine method-of-use c
Slide 24: STENDRA Prescribing Information
STENDRA PRESCRIBING INFORMATION About STENDRA™ STENDRA is a prescription medicine used to treat erectile dysfunction (ED). STENDRA (avanafil) is licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS has development and commercial rights to STENDRA for the treatment of sexual dysfunction worldwid
Slide 25: Avanafil Partnerships / Update
AVANAFIL PARTNERSHIPS / UPDATE Request submitted to FDA for revised label 15 minute onset; PDUFA 20-Sep-2014 Auxilium Pharmaceuticals, Inc. - U.S. & Canada U.S. launched Menarini - 40 Countries in Europe + AUS/NZ To date, France, Germany, Italy and U.K. launched Sanofi - Africa, Middle East, Turkey,
Slide 26: VIVUS Priorities - 2014
VIVUS PRIORITIES - 2014 Drive Qsymia Demand Increase Third Party Coverage for Qsymia Enhance Direct-to-Patient Programs Establish a Qsymia Commercial Alliance Maintain Positive Momentum for STENDRA/SPEDRA Alliances ©2014 VIVUS Inc. All rights reserved | www.vivus.com 25
Slide 27: Innovative Therapies Novel Products
INNOVATIVE THERAPIES NOVEL PRODUCTS April 2014 ©2014 VIVUS Inc. All rights reserved | www.vivus.com